Show simple item record

dc.contributor.authorBrandao, Ajacio Bandeira de Mellopt_BR
dc.contributor.authorRodríguez, Santiagopt_BR
dc.contributor.authorFleck Júnior, Alfeu de Medeirospt_BR
dc.contributor.authorMarroni, Claudio Augustopt_BR
dc.contributor.authorWagner, Mario Bernardespt_BR
dc.contributor.authorHorbe, Alex Fingerpt_BR
dc.contributor.authorFernandes, Matheus Vanzinpt_BR
dc.contributor.authorCerski, Carlos Thadeu Schmidtpt_BR
dc.contributor.authorCoral, Gabriela Perdomopt_BR
dc.date.accessioned2023-11-11T03:24:22Zpt_BR
dc.date.issued2022pt_BR
dc.identifier.issn2218-4333pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/266990pt_BR
dc.description.abstractBACKGROUND Cholangiocarcinoma (CC) is a rare tumor that arises from the epithelium of the bile ducts. It is classified according to anatomic location as intrahepatic, perihilar, and distal. Intrahepatic CC (ICC) is rare in patients with cirrhosis due to causes other than primary sclerosing cholangitis. Mixed hepatocellular carcinoma-CC (HCC-CC) is a rare neoplasm that shows histologic findings of both HCC and ICC within the same tumor mass. Due to the difficulties in arriving at the correct diagnosis, patients eventually undergo liver transplantation (LT) with a presumptive diagnosis of HCC on imaging when, in fact, they have ICC or HCC-CC. AIM To evaluate the outcomes of patients with intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma on pathological examination after liver transplant. METHODS Propensity score matching was used to analyze tumor recurrence (TR), overall mortality (OM), and recurrence-free survival (RFS) in LT recipients with pathologically confirmed ICC or HCC-CC matched 1:8 to those with HCC. Progression-free survival and overall mortality rates were computed with the Kaplan-Meier method using Cox regression for comparison. RESULTS Of 475 HCC LT recipients, 1.7% had the diagnosis of ICC and 1.5% of HCC-CC on pathological examination of the explant. LT recipients with ICC had higher TR (46% vs 11%; P = 0.006), higher OM (63% vs 23%; P = 0.002), and lower RFS (38% vs 89%; P = 0.002) than those with HCC when matched for pretransplant tumor characteristics, as well as higher TR (46% vs 23%; P = 0.083), higher OM (63% vs 35%; P = 0.026), and lower RFS (38% vs 59%; P = 0.037) when matched for posttransplant tumor characteristics. Two pairings were performed to compare the outcomes of LT recipients with HCC-CC vs HCC. There was no significant difference between the outcomes in either pairing. CONCLUSION Patients with ICC had worse outcomes than patients undergoing LT for HCC. The outcomes of patients with HCC-CC did not differ significantly from those of patients with HCC.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofWorld journal of clinical oncology. Pleasanton. Vol. 13, no. 8 (Aug. 2022), p. 688-701pt_BR
dc.rightsOpen Accessen
dc.subjectCholangiocarcinomaen
dc.subjectTransplante de fígadopt_BR
dc.subjectHepatocellular carcinomaen
dc.subjectPrognósticopt_BR
dc.subjectLiveren
dc.subjectCarcinoma hepatocelularpt_BR
dc.subjectColangiocarcinomapt_BR
dc.subjectPrognosisen
dc.subjectRecurrenceen
dc.subjectSurvival analysisen
dc.subjectTransplantationen
dc.titlePropensity-matched analysis of patients with intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma and hepatocellular carcinoma undergoing a liver transplantpt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb001186996pt_BR
dc.type.originEstrangeiropt_BR


Files in this item

Thumbnail
Thumbnail
   

This item is licensed under a Creative Commons License

Show simple item record